Efient, INN-Prasugrel
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Additions and Deletions to the Drug Product List
Prescription and Over-the-Counter Drug Product List 40TH EDITION Cumulative Supplement Number 09 : September 2020 ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE >A> AA STRIDES PHARMA 325MG;50MG;40MG A 203647 001 Sep 21, 2020 Sep NEWA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >D> AA WOCKHARDT BIO AG 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC >A> @ 120MG/5ML;12MG/5ML A 087006 001 Jul 22, 1981 Sep DISC TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE >A> AA NOSTRUM LABS INC 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >A> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >A> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN >D> AA TEVA 300MG;15MG A 088627 001 Mar 06, 1985 Sep CAHN >D> AA 300MG;30MG A 088628 001 Mar 06, 1985 Sep CAHN >D> AA ! 300MG;60MG A 088629 001 Mar 06, 1985 Sep CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN >A> @ CEROVENE INC 325MG;5MG A 211690 001 Feb 07, 2020 Sep CAHN >A> @ 325MG;7.5MG A 211690 002 Feb 07, 2020 Sep CAHN >A> @ 325MG;10MG A 211690 003 Feb 07, 2020 Sep CAHN >D> AA VINTAGE PHARMS 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >A> @ 300MG;5MG A 090415 001 Jan 24, 2011 Sep DISC >D> AA 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >A> @ 300MG;7.5MG A 090415 002 Jan 24, 2011 Sep DISC >D> AA 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >A> @ 300MG;10MG A 090415 003 Jan 24, 2011 Sep DISC >D> @ XIROMED 325MG;5MG A 211690 -
Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human Ntpdase1
Hindawi Publishing Corporation Mediators of Inflammation Volume 2014, Article ID 547480, 8 pages http://dx.doi.org/10.1155/2014/547480 Research Article Ticlopidine in Its Prodrug Form Is a Selective Inhibitor of Human NTPDase1 Joanna Lecka,1,2 Michel Fausther,1,2 Beat Künzli,3 and Jean Sévigny1,2 1 Departement´ de Microbiologie-Infectiologie et d’Immunologie, FacultedeM´ edecine,´ UniversiteLaval,Qu´ ebec,´ QC, Canada G1V 0A6 2 Centre de Recherche du CHU de Quebec,´ 2705 Boulevard Laurier, Local T1-49, Quebec,´ QC, Canada G1V 4G2 3 Department of Surgery, Klinikum Rechts der Isar, Technische Universitat¨ Munchen,¨ 81675 Munich, Germany Correspondence should be addressed to Jean Sevigny;´ [email protected] Received 12 May 2014; Accepted 21 July 2014; Published 11 August 2014 Academic Editor: Mireia Mart´ın-Satue´ Copyright © 2014 Joanna Lecka et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Nucleoside triphosphate diphosphohydrolase-1 (NTPDase1), like other ectonucleotidases, controls extracellular nucleotide levels and consequently their (patho)physiological responses such as in thrombosis, inflammation, and cancer. Selective NTPDase1 inhibitors would therefore be very useful. We previously observed that ticlopidine in its prodrug form, which does not affect P2 receptor activity, inhibited the recombinant form of human NTPDase1 ( =14M). Here we tested whether ticlopidine can be used as a selective inhibitor of NTPDase1. We confirmed that ticlopidine inhibits NTPDase1 in different forms and in different assays. The ADPase activity of intact HUVEC as well as of COS-7 cells transfected with human NTPDase1 was strongly inhibited by 100 M ticlopidine, 99 and 86%, respectively. -
P2 Receptors in Cardiovascular Regulation and Disease
Purinergic Signalling (2008) 4:1–20 DOI 10.1007/s11302-007-9078-7 REVIEW P2 receptors in cardiovascular regulation and disease David Erlinge & Geoffrey Burnstock Received: 3 May 2007 /Accepted: 22 August 2007 /Published online: 21 September 2007 # Springer Science + Business Media B.V. 2007 Abstract The role of ATP as an extracellular signalling Introduction molecule is now well established and evidence is accumulating that ATP and other nucleotides (ADP, UTP and UDP) play Ever since the first proposition of cell surface receptors for important roles in cardiovascular physiology and pathophysi- nucleotides [1, 2], it has become increasingly clear that, in ology, acting via P2X (ion channel) and P2Y (G protein- addition to functioning as an intracellular energy source, the coupled) receptors. In this article we consider the dual role of purines and pyrimidines ATP, adenosine diphosphate ATP in regulation of vascular tone, released as a cotransmitter (ADP), uridine triphosphate (UTP) and uridine diphosphate from sympathetic nerves or released in the vascular lumen in (UDP) can serve as important extracellular signalling response to changes in blood flow and hypoxia. Further, molecules [3, 4] acting on 13 P2X homo- and heteromul- purinergic long-term trophic and inflammatory signalling is timer ionotropic and 8 P2Y metabotropic receptor subtypes described in cell proliferation, differentiation, migration and [5, 6] (Table 1). To terminate signalling, ectonucleotidases death in angiogenesis, vascular remodelling, restenosis and are present in the circulation and on cell surfaces, rapidly atherosclerosis. The effects on haemostasis and cardiac degrading extracellular ATP into ADP, AMP and adenosine regulation is reviewed. The involvement of ATP in vascular [7, 8]. -
Prasugrel Mylan 10 Mg Film-Coated Tablets Prasugrel
Package leaflet: Information for the user Prasugrel Mylan 5 mg film-coated tablets Prasugrel Mylan 10 mg film-coated tablets prasugrel Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor or pharmacist. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Prasugrel Mylan is and what it is used for 2. What you need to know before you take Prasugrel Mylan 3. How to take Prasugrel Mylan 4. Possible side effects 5. How to store Prasugrel Mylan 6. Contents of the pack and other information 1. What Prasugrel Mylan is and what it is used for Prasugrel Mylan, which contains the active substance prasugrel, belongs to a group of medicines called antiplatelet agents. Platelets are very small cell particles that circulate in the blood. When a blood vessel is damaged, for example if it is cut, platelets clump together to help form a blood clot (thrombus). Therefore, platelets are essential to help stop bleeding. If clots form within a hardened blood vessel such as an artery they can be very dangerous as they can cut off the blood supply, causing a heart attack (myocardial infarction), stroke or death. -
Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11. -
Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations
molecules Review Salts of Therapeutic Agents: Chemical, Physicochemical, and Biological Considerations Deepak Gupta 1, Deepak Bhatia 2 ID , Vivek Dave 3 ID , Vijaykumar Sutariya 4 and Sheeba Varghese Gupta 4,* 1 Department of Pharmaceutical Sciences, School of Pharmacy, Lake Erie College of Osteopathic Medicine, Bradenton, FL 34211, USA; [email protected] 2 ICPH Fairfax Bernard J. Dunn School of Pharmacy, Shenandoah University, Fairfax, VA 22031, USA; [email protected] 3 Wegmans School of Pharmacy, St. John Fisher College, Rochester, NY 14618, USA; [email protected] 4 Department of Pharmaceutical Sciences, USF College of Pharmacy, Tampa, FL 33612, USA; [email protected] * Correspondence: [email protected]; Tel.: +01-813-974-2635 Academic Editor: Peter Wipf Received: 7 June 2018; Accepted: 13 July 2018; Published: 14 July 2018 Abstract: The physicochemical and biological properties of active pharmaceutical ingredients (APIs) are greatly affected by their salt forms. The choice of a particular salt formulation is based on numerous factors such as API chemistry, intended dosage form, pharmacokinetics, and pharmacodynamics. The appropriate salt can improve the overall therapeutic and pharmaceutical effects of an API. However, the incorrect salt form can have the opposite effect, and can be quite detrimental for overall drug development. This review summarizes several criteria for choosing the appropriate salt forms, along with the effects of salt forms on the pharmaceutical properties of APIs. In addition to a comprehensive review of the selection criteria, this review also gives a brief historic perspective of the salt selection processes. Keywords: chemistry; salt; water solubility; routes of administration; physicochemical; stability; degradation 1. -
A Comparative Study of Molecular Structure, Pka, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs
International Journal of Molecular Sciences Article A Comparative Study of Molecular Structure, pKa, Lipophilicity, Solubility, Absorption and Polar Surface Area of Some Antiplatelet Drugs Milan Remko 1,*, Anna Remková 2 and Ria Broer 3 1 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Comenius University in Bratislava, Odbojarov 10, SK-832 32 Bratislava, Slovakia 2 Department of Internal Medicine, Faculty of Medicine, Slovak Medical University, Limbová 12, SK–833 03 Bratislava, Slovakia; [email protected] 3 Department of Theoretical Chemistry, Zernike Institute for Advanced Materials, University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands; [email protected] * Correspondence: [email protected]; Tel.: +421-2-5011-7291 Academic Editor: Michael Henein Received: 18 February 2016; Accepted: 11 March 2016; Published: 19 March 2016 Abstract: Theoretical chemistry methods have been used to study the molecular properties of antiplatelet agents (ticlopidine, clopidogrel, prasugrel, elinogrel, ticagrelor and cangrelor) and several thiol-containing active metabolites. The geometries and energies of most stable conformers of these drugs have been computed at the Becke3LYP/6-311++G(d,p) level of density functional theory. Computed dissociation constants show that the active metabolites of prodrugs (ticlopidine, clopidogrel and prasugrel) and drugs elinogrel and cangrelor are completely ionized at pH 7.4. Both ticagrelor and its active metabolite are present at pH = 7.4 in neutral undissociated form. The thienopyridine prodrugs ticlopidine, clopidogrel and prasugrel are lipophilic and insoluble in water. Their lipophilicity is very high (about 2.5–3.5 logP values). The polar surface area, with regard to the structurally-heterogeneous character of these antiplatelet drugs, is from very large interval of values of 3–255 Å2. -
Preventive Medication Program
PREVENTIVE MEDICATION PROGRAM Generics and Preferred Brands Drug List Starting July 1, 2021 Preventive medications are used to prevent certain conditions from developing, or to prevent a condition from coming back. These conditions include, but are not limited to, asthma, depression, diabetes, heart attack, high blood pressure, high cholesterol, osteoporosis, prenatal nutrient deficiency and stroke. About this drug list. Your cost-share for preventive generic and This is a list of the most commonly prescribed generic preferred brand medications. and preferred brand medications that are part of Not all plans offer the same cost-share for their Cigna’s preventive medication program as of July preventive medication program. For example, some 1, 2021.1,2 This drug list is updated often so it isn’t a plans may require you to pay a copay, coinsurance complete list of medications. Also, your specific plan’s and/or deductible for preventive generic and preferred preventive medication program may not include all brand medications; other plans may not. of these medications and/or conditions. Log in to the Log into the myCigna App or myCigna.com and use myCigna® App or myCigna.com, or check your plan the Price a Medication tool to see how much your materials, to see all of the medications included in your medication may cost you at the different pharmacies in plan’s preventive medication program and how much your plan’s network.3 they cost. Here’s some helpful information about this drug list: › Medications are listed alphabetically by condition. › Brand-name medications are capitalized and generic medications are lowercase. -
Wo 2010/075090 A2
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 1 July 2010 (01.07.2010) WO 2010/075090 A2 (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 409/14 (2006.01) A61K 31/7028 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 409/12 (2006.01) A61P 11/06 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2009/068073 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 15 December 2009 (15.12.2009) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, (26) Publication Language: English TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/122,478 15 December 2008 (15.12.2008) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): AUS- ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, PEX PHARMACEUTICALS, INC. -
Preventive Generic Drugs Listing
2017 PREVENTIVE DRUG LIST Preventive medications are used for the prevention of conditions such as high blood pressure, high cholesterol, diabetes, asthma, osteoporosis, heart attack, stroke and prenatal nutrient deficiency. You may not have to pay a copay, a coinsurance (the percentage you pay after you meet your deductible) and/or a deductible (the amount you pay before your plan starts to pay) for preventive medications. Please check your plan’s prescription drug list and This list is subject to change and may not include all plan documents to understand how your plan covers preventive medications that your plan covers. Please preventive medications. You can refer to myCigna.com refer to your plan’s prescription drug list for a complete for a complete and up-to-date drug listing for your plan. and up-to-date drug listing. You can also use the Prescription Drug Price Quote tool on myCigna.com to view and compare drug prices. The following is a list of generic and brand-name If you have questions preventive medications, arranged by type of condition. Please call the toll-free number on the back of Talk with your doctor when choosing the preventive your Cigna ID card. We’re here to help. medication that is right for you. Also talk with your doctor about available generic preventive medications (listed as uncapitalized medications and/or in parentheses). Generic medications have the same active ingredients, dosage form, quality and strength, as their brand-name counterparts and may provide additional savings for you. Offered by: Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, or their affiliates. -
Dissertation.Pdf
UNIVERSITÄTSKLINIKUM HAMBURG-EPPENDORF Zentrum für Experimentelle Medizin, Institut für Experimentelle Pharmakologie und Toxikologie Direktor: Professor T. Eschenhagen Thrombus-Targeted Theranostic Microbubbles for Simultaneous Ultrasound Diagnosis and Therapy of Thrombosis. Title page Dissertation zur Erlangung des Grades eines Doktors der Medizin an der Medizinischen Fakultät der Universität Hamburg. vorgelegt von: Yannik Andreas Gkanatsas aus Bremen Hamburg 2017 Angenommen von der Medizinischen Fakultät der Universität Hamburg am: 13.12.2017 Veröffentlicht mit Genehmigung der Medizinischen Fakultät der Universität Hamburg. Prüfungsausschuss, der Vorsitzende: Prof. Dr. Thomas Eschenhagen Prüfungsausschuss, zweite Gutachterin: Prof. Dr. Renate Bonin-Schnabel Prüfungsausschuss, dritter Gutachter: PD Dr. Florian Langer 2 Table of contents Title page ..................................................................................................................... 1 Table of contents ......................................................................................................... 3 List of Figures: ............................................................................................................. 6 List of Tables: .............................................................................................................. 7 Chapter 1. Introduction ............................................................................................. 8 1.1 Cardiovascular Disease (CVD) ......................................................................................... -
MEDICINE to TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What Are These Medicines U
PATIENT INFORMATION LEAFLET MEDICINE TO TREAT: HEART DISEASES Antiplatelet Agents Aspirin Dipyridamole Clopidogrel Ticlopidine 1. What are these medicines used for? Medicine Purpose of medicine Brand Names This medicine makes blood less sticky to reduce the chance of blood forming Aspirin Cardiprin® clots which will lead to stroke or heart Disprin® attack. This medicine makes the blood less Dipyridamole sticky to reduce the chance of stroke. It Persantin® is used together with aspirin. These medicines make your blood less Clopidogrel (Plavix®) Clopidogrel sticky to reduce chance of stroke or Ticlopidine (Ticlid®), Ticlopidine heart attack. They can be used alone or together with aspirin. 2. How should I take the medicines? • Do not stop taking your medicines without checking with your doctors. • If you miss a dose, take the missed dose as soon as you remember. If it is almost time for your next dose, take only the usual dose. Do not double your dose or use extra medicine to make up for the missed dose. • You should take your medicine after a meal to prevent stomach upset. • How you take aspirin depends on the brand and type of aspirin the doctor gives you: o For tablets which can be chewed: Take with food or glass of water or milk These tablets may be chewed or swallowed whole The solution may also be used as a gargle. Please check with your pharmacist on how to use it as a gargle. o For tablets which enteric coated: Enteric coated forms of aspirin reduce stomach upset that is caused by the medicine Take with a glass of water after food.